Proprio secures $43 million in Series B funding to expand its AI-enabled surgical navigation platform, Paradigm, which offers real-time 3D visualizations of surgeries. The investment will drive platform adoption and revolutionize surgical procedures. MediView XR, a competitor in the market, utilizes augmented reality for surgical navigation and recently received FDA clearance for its XR90 offering, enabling 3D visualization of a patient’s internal structures based on CT images. The medical industry’s growing interest in surgical navigation platforms has led to strategic investments in both Proprio and MediView XR to enhance surgical precision and patient outcomes.
Seattle-based AI-enabled surgical technology company, Proprio, has successfully raised $43 million in Series B funding, attracting both new and existing investors, including Bird B. The significant investment will be utilized to fuel the expansion and adoption of their FDA-cleared surgical navigation platform, known as Paradigm.
Paradigm, the flagship product of Proprio, stands out for its cutting-edge use of light field technology and artificial intelligence, which collaboratively create real-time 3D visualizations of surgical procedures. This revolutionary approach enables surgeons to view intraoperative scans with unprecedented clarity. Additionally, Proprio offers Volumetric Intelligence, a platform that merges medical images with data gathered by Paradigm’s sensors.
The infusion of funds will be crucial as Proprio gears up to carry out its first-in-human cases and make Paradigm accessible to patients worldwide. Gabriel Jones, CEO, and co-founder of Proprio, expressed his excitement about this investment, emphasizing how it will facilitate their mission to revolutionize the field of surgery.
In 2020, Proprio made significant strides with a successful Series A financing round, securing $23 million. However, the recent Series B funding signifies another milestone in their journey to further advance surgical navigation technology.
In the market snapshot, another notable player in the surgical navigation space is MediView XR. This platform harnesses augmented reality visualization and surgical navigation, with its XR90 offering having received FDA clearance recently. Providers can utilize this technology to gain a comprehensive 3D view of a patient’s internal soft tissues, vascular, organ, and skeletal structures based on their CT images.
Overall, the medical industry’s interest in surgical navigation platforms has led to strategic investments in companies like Proprio and MediView XR, with both firms striving to push the boundaries of surgical precision and patient outcomes.
